Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

2.92
+0.02000.69%
Post-market: 2.970.0500+1.71%18:02 EST
Volume:53.58K
Turnover:153.91K
Market Cap:97.46M
PE:-8.67
High:2.93
Open:2.88
Low:2.83
Close:2.90
52wk High:5.46
52wk Low:2.33
Shares:33.38M
Float Shares:30.46M
Volume Ratio:0.44
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3367
EPS(LYR):-0.3367
ROE:-67.17%
ROA:-38.83%
PB:6.43
PE(LYR):-8.67

Loading ...

BRIEF-Anixa Biosciences Reports Encouraging Patient Survival Observations In Ovarian Cancer Car-T Trial

Reuters
·
Feb 09

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

THOMSON REUTERS
·
Feb 09

EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues

Benzinga_recent_news
·
Feb 09

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 04

Anixa Biosciences Receives USAN Council Approval for CAR-T Therapy Name

Reuters
·
Feb 02

Anixa Biosciences Inc - Approved 'Liraltagene Autoleucel' for Fshr-Targeted CAR-T Therapy

THOMSON REUTERS
·
Feb 02

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for Its CAR-T Therapy, a Key Step Toward Future Commercialization

THOMSON REUTERS
·
Feb 02

Insider Move: Anixa Biosciences Director Makes Bold New Bet on the Stock

TIPRANKS
·
Jan 30

Anixa Biosciences Director Arnold M. Baskies Reports Acquisition of Common Shares

Reuters
·
Jan 29

Anixa Biosciences granted patent for breast cancer vaccine technology in Mexico

TIPRANKS
·
Jan 27

Anixa Biosciences Receives Notice of Allowance From Mexican Institute of Industrial Property (Impi) for Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
Jan 27

Anixa Biosciences posts FY2025 interest income of USD 0.7 million, down 41 percent

Reuters
·
Jan 13

Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial

Reuters
·
Dec 15, 2025

Anixa Biosciences Announces Transfer of Ind for Breast Cancer Vaccine From Cleveland Clinic

THOMSON REUTERS
·
Dec 15, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:41 AM

Reuters
·
Dec 12, 2025

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 12, 2025

Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine

Reuters
·
Dec 12, 2025

Anixa Biosciences Inc - Vaccine Safe and Well Tolerated at Maximum Dose

THOMSON REUTERS
·
Dec 12, 2025

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

THOMSON REUTERS
·
Dec 12, 2025

Anixa Biosciences CEO to Join Water Tower Research Fireside Chat

Reuters
·
Dec 10, 2025